Biomarkers in IBD: What to Utilize for the Diagnosis?

• Published in: Diagnostics (Basel) Vol. 13; no. 18; p. 2931
• Main Authors: D’Incà, Renata, Sturniolo, Giulia
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01-09-2023; MDPI
• Subjects: Anemia; Antibodies; ASCA; Biological markers; Biomarkers; Blood; Blood tests; C-reactive protein; Carbohydrates; Crohns disease; Ethylenediaminetetraacetic acid; fecal calprotectin; Immunology; Inflammation; Inflammatory bowel disease; Iron; Medical examination; Neutrophils; p-ANCA; Patients; Pediatrics; Review; Serology; Ulcerative colitis; Viral antibodies
• ISSN: 2075-4418; 2075-4418
• DOI: 10.3390/diagnostics13182931

The role of biomarkers in the diagnosis of inflammatory bowel disease is not fully characterized. C-reactive protein has a short half-life and elevates quickly after the onset of an inflammatory process; the performance is better in Crohn’s disease than in ulcerative colitis. Erythrocyte sedimentation rate is easy to determine, widely available, and cheap, but the long half-life, the influence of age, anemia, smoking, and drugs limit its usefulness. Fecal markers have good specificity, but suboptimal accuracy. Microbial antibodies and novel immunological markers show promise but need further evidence before entering clinical practice. Proteomic methods could represent the dawn of a new era of stool protein/peptide biomarker panels able to select patients at risk of inflammatory bowel disease.